Senior Statistician
Jan 2022 – Present- Lead statistician on 2 Phase III oncology trials enrolling 1,100 patients, supporting a successful NDA submission
- Authored statistical analysis plans with estimands aligned to ICH E9(R1)
- Designed a group-sequential interim analysis that allowed early stopping for efficacy, saving 9 months
- Reviewed ADaM datasets and TLFs from 2 CROs, catching 30 programming discrepancies before database lock